Cancer News and Research

Latest Cancer News and Research

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced updated Phase 1/2 clinical trial results related to the Company's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the ASCO Gastro Intestinal Cancers Symposium that took place in San Francisco from January 20-22, 2011.

24 Jan 2011

Senesco files SNS01-T IND for treatment of multiple myeloma

Senesco Technologies, Inc. today announced that the Company has filed an Investigational New Drug application with the U.S. Food and Drug Administration for Senesco's lead drug candidate SNS01-T for treatment of multiple myeloma.

24 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

Rogue gene blocked by right drugs could stop cancer

Scientists at the University of East Anglia (UEA) have discovered a rogue gene which - if blocked by the right drugs - could stop cancer in its tracks.

24 Jan 2011

Contagious cancer repairs own genetic mutations

A curious contagious cancer, found in dogs, wolves and coyotes, can repair its own genetic mutations by adopting genes from its host animal, according to a new study in the journal Science.

24 Jan 2011

KineMed's fibrosis research program featured in Nature Medicine

KineMed Inc.'s fibrosis research program, which aims to advance the discovery and development of drugs to treat this major disease, is featured in the January edition of Nature Medicine.

24 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BioDelivery Sciences International, Inc. today responded to a process patent infringement lawsuit filed and recently served against the Company and certain co-defendants by MonoSol Rx, LLC. The purpose in responding at this time is for BDSI to strongly refute MonoSol's claims and to assure BDSI stockholders that the Company remains focused on vigorously progressing its pipeline and not allowing this claim to present a distraction.

24 Jan 2011

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Jan 2011

Healthcare workers can help improve quality of life for end of life patients

Healthcare workers can most directly affect quality of life (QOL) of patients with advanced stage lung cancer by helping manage symptoms such as pain, lack of energy, shortness of breath, coughing, difficulty sleeping and dry mouth, according to a study recently published in the journal Oncology Nursing Forum.

24 Jan 2011

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Immune Network, a company in the business of development and commercialization of immune therapies, announced today that its newly acquired business, Immunitor, has published interim data from the ongoing Phase IIb imm01 clinical trial of V5 in tuberculosis conducted at its second site in Ukraine.

24 Jan 2011

Radiation Therapy Services to issue $50M of 9-7/8% Senior Subordinated Notes due 2017

Radiation Therapy Services Holdings, Inc.announced today that its wholly owned subsidiary, Radiation Therapy Services, Inc., has agreed to issue an aggregate principal amount of $50 million of 9-7/8% Senior Subordinated Notes due 2017.

24 Jan 2011

MGH research sheds light on mechanisms of action of mindfulness-based training

Participating in an 8-week mindfulness meditation program appears to make measurable changes in brain regions associated with memory, sense of self, empathy and stress. In a study that will appear in the January 30 issue of Psychiatry Research: Neuroimaging, a team led by Massachusetts General Hospital researchers report the results of their study, the first to document meditation-produced changes over time in the brain's grey matter.

24 Jan 2011

Research findings reveal HIV's hiding spot, new way to stop the virus

HIV adapts in a surprising way to survive and thrive in its hiding spot within the human immune system, scientists have learned. While the finding helps explain why HIV remains such a formidable foe after three decades of research - more than 30 million people worldwide are infected with HIV - it also offers scientists a new, unexpected way to try to stop the virus.

24 Jan 2011

Eckert & Ziegler receives European Commission's indefinite approval for YTTRIGA

Eckert & Ziegler Strahlen- und Medizintechnik AG, a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five years ago the European Medicines Agency EMA approved this drug for the first time and as a result of the current renewal process the drug has now been granted an indefinite approval.

24 Jan 2011

CT scans can help physicians to diagnose abdominal pain, reduce health care costs

The use of CT scanning to evaluate abdominal pain in emergency departments can help physicians arrive at a diagnosis quickly and decisively. A study conducted at Massachusetts General Hospital and appearing in the February issue of the American Journal of Roentgenology also finds that information provided by CT scans changed treatment plans for almost half the patients studied and significantly reduced probable hospital admissions.

24 Jan 2011

Scientists ignore relevant drug clinical trials when conducting new research on same topic

The vast majority of already published and relevant clinical trials of a given drug, device or procedure are routinely ignored by scientists conducting new research on the same topic, a new Johns Hopkins study suggests.

24 Jan 2011

Los Angeles Society of Pathologists honors LA BioMed researcher with Lifetime Achievement Award

The Los Angeles Society of Pathologists, Inc. presented its Lifetime Achievement Award to Samuel W. French, MD, a principal investigator at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, on Jan. 15.

24 Jan 2011

Cancer News and Research

Latest Cancer News and Research

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Senesco files SNS01-T IND for treatment of multiple myeloma

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Rogue gene blocked by right drugs could stop cancer

Contagious cancer repairs own genetic mutations

KineMed's fibrosis research program featured in Nature Medicine

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Healthcare workers can help improve quality of life for end of life patients

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Radiation Therapy Services to issue $50M of 9-7/8% Senior Subordinated Notes due 2017

MGH research sheds light on mechanisms of action of mindfulness-based training

Research findings reveal HIV's hiding spot, new way to stop the virus

Eckert & Ziegler receives European Commission's indefinite approval for YTTRIGA

CT scans can help physicians to diagnose abdominal pain, reduce health care costs

Scientists ignore relevant drug clinical trials when conducting new research on same topic

Los Angeles Society of Pathologists honors LA BioMed researcher with Lifetime Achievement Award

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in